HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oréal

This article was originally published in The Rose Sheet

Executive Summary

Acquisition of tissue engineering company SkinEthic by French beauty marketer's Episkin subsidiary, which is dedicated to development of reconstructed skin, is aimed at helping L'Oréal enhance development of in vitro test methods, firm says in Feb. 28 release. SkinEthic is an "important worldwide player in the production and commercialization of human epidermal and epithelial tissues," including epidermis, dermis and corneal tissues, L'Oréal notes. "The acquisition of SkinEthic allows us to respond to the needs of the entire industry and more specifically in the area of alternative approaches to animal testing," firm adds. Marketing of most cosmetic products tested on animals is prohibited under 7th Amendment to EU's Cosmetics Directive beginning in 2009...

You may also be interested in...



US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel